Researchers find powerful combo weapon against aggressive lymphoma

The targeted therapy combination of ibrutinib and venetoclax significantly improved progression-free survival (PFS) and achieved an overall remission rate in 82% of patients with relapsed/refractory mantle cell lymphoma (MCL), according to researchers at The University of Texas MD Anderson Cancer Center. Results from the Phase III SYMPATICO trial were presented at the 2023 American Society of Hematology (ASH) Annual Meeting.

Zombie Investments: The State of Private Equity in Healthcare

Greg Hagood, President of SOLIC Capital, LLC Private equity (PE) firms, once eager investors in the healthcare services sector, are facing a chilling reality. A

October 22, 2024

Vita Health Secures $22.5M to Combat Suicide and Mental Health Crisis Nationwide

What You Should Know: Vita Health, the first provider of clinically validated suicide prevention through innovative care management, announced today the close of a $22.5M Series

January 10, 2024

FTC and DOJ propose changes that could slow dealmaking review process

The Federal Trade Commission and Justice Department have proposed changes to the merger review process that could extend the amount of time and documentation it

June 30, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.